Home > News > APP Announces Positive Results of Intra-Arterial ABI-007
June 4th, 2003
APP Announces Positive Results of Intra-Arterial ABI-007
At the American Society of Clinical Oncology annual meeting held in Chicago, Illinois, American Pharmaceutical Partners, Inc. said that investigators from the Insituto dei Tumori in Milan, Italy, reported on their experience in 108 patients receiving high dose ABI-007, a novel cremophor-free protein engineered nanoparticle paclitaxel, by the intra-arterial route.
Malvern specialist to explore use of Nanoparticle Tracking Analysis for characterizing extracellular vesicles at ISEV 2014 March 11th, 2014
Arrowhead to Present at Barclays Global Healthcare Conference March 11th, 2014
Production of Bioactive Material for Quick Treatment of Bone Damages March 10th, 2014
Production of New Type of Electrochemical Drug Sensors for Cardiovascular Diseases March 10th, 2014